Osaka, Japan, February 28, 2014 – Takeda Pharmaceutical Company Limited (Takeda) confirmed today Mr. Christophe Weber’s official start date as Takeda’s Chief Operating Officer (COO) is April 1, 2014. Mr. Weber is expected to become President and Representative Director, in addition to COO upon approval at Takeda's Ordinary General Meeting of Shareholders and the Board of Directors Meeting in late June 2014. At that time, the current President and Chief Executive Officer (CEO), Mr. Yasuchika Hasegawa, will assume the role of Chairman and CEO.
Upon becoming COO, Mr. Weber will be responsible for all operational activities and report to Mr. Hasegawa. As Chairman and CEO, Mr. Hasegawa will continue to take responsibility for the mid-to-long-term corporate strategy as well as important global management policies.
“I expect that Mr. Weber’s rich business leadership and diverse experience will strengthen Takeda in all regions, including Japan, and contribute to the acceleration of our growth and development,” said Mr. Yasuchika Hasegawa, President and CEO.
Upon appointment as COO, Mr. Weber will reside in Japan, conducting his duties from Tokyo.
Takeda’s mission is to strive towards better health for people worldwide through leading innovation in medicine and continue to transform into a truly global pharmaceutical company that responds to the diverse medical needs around the world while at the same time fulfilling its obligations to stakeholders.
Internal Disclaimer Body